CRISPR Therapeutics AG (CRSP) Non-Current Deffered Revenue (2015 - 2025)

CRISPR Therapeutics AG has disclosed Non-Current Deffered Revenue across 11 years of filings, most recently posting $12.3 million for Q3 2025.

• In Q3 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $12.3 million; the TTM figure through Sep 2025 stood at $12.3 million (changed 0.0% YoY), while the FY2024 annual figure was $12.3 million, down 12.05% from the prior year.
• Non-Current Deffered Revenue came in at $12.3 million for Q3 2025 at CRISPR Therapeutics AG, roughly flat from $12.3 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $15.8 million in Q3 2023 to a low of $11.8 million in Q2 2021.
• Average Non-Current Deffered Revenue over 5 years is $12.6 million, with a median of $12.3 million recorded in 2021.
• Year-over-year, Non-Current Deffered Revenue gained 28.4% in 2023 and decreased 22.12% in 2024.
• Over 5 years, Non-Current Deffered Revenue stood at $12.3 million in 2021, then changed by 0.0% to $12.3 million in 2022, then climbed by 13.71% to $14.0 million in 2023, then retreated by 12.05% to $12.3 million in 2024, then changed by 0.0% to $12.3 million in 2025.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $12.3 million in Q3 2025, $12.3 million in Q2 2025, and $12.3 million in Q1 2025.